Dual-listed Enlivex Therapeutics, whose share price shot up in Tel Aviv yesterday after it announced that its Allocetra product for treating sepsis could benefit Covid-19 coronavirus patients, exploited the momentum to raise $8 million at a discount on the market price of its shares, and in response its share price fell by 6.3% in New York by yesterday's close. RELATED ARTICLES Israel's Enlivex reports drug could help COVID-19 patients The closing price is still 9% higher than the price at which Enlivex raised the funds, but substantially lower than the price that the stock reached during yesterday's session. The company's market cap is now some $90 million, and it has fallen by about 40% in Tel Aviv this morning after opening on a wide negative arbitrage gap. Published by Globes, Israel business news - en.globes.co.il - on February 25, 2020 © Copyright of Globes Publisher Itonut (1983) Ltd. 2020
